Johns Hopkins Bloomberg School of Public Health, Department of International Health, 615 N. Wolfe Street, Room W5009, Baltimore, MD 21205-2103, USA.
Seattle Children's Hospital and Research Foundation, University of Washington, 4800 Sand Point Way N.E., R5441, Seattle, WA 98105, USA.
Vaccine. 2017 Dec 4;35(48 Pt B):6743-6750. doi: 10.1016/j.vaccine.2017.09.095. Epub 2017 Oct 31.
Maternal influenza vaccination has increased birth weight in two randomized trials in South Asia but the impact on infant growth is unknown.
A randomized placebo-controlled trial of year round maternal influenza immunization was conducted in two annual cohorts in Sarlahi District, southern plains of Nepal, from April 2011 through April 2014. Infants born to women enrolled in the trial had weight, length, and head circumference measured at birth and 6 months of age. The study was powered for the 3 primary trial outcomes but not for stunting and wasting at 6 months of age.
3693 women received placebo or influenza vaccine between 17 and 34 weeks gestation, resulting in 3646 live births. About 72% of infants who survived had weight and length measurements between 150 and 210 days of age. Prevalence of stunting (<-2 Z scores length-for-age) was 14.8% in the placebo and 13.6% in the vaccine groups, respectively. Stunting < -3 Z scores was 3.2% versus 2.0% in placebo versus vaccine groups (RR: 0.64 (95% CI: 0.39, 1.04)). Wasting (< -2 Z scores weight for length) was 10.3% versus 11.0% for placebo versus vaccine groups. Severe wasting (< -3 Z scores weight for length) was 3.8% for placebo versus 2.6% for vaccine (RR: 0.69 (95% CI: 0.44, 1.07)). The impact of flu vaccine on wasting was greater in cohort 2 than in cohort 1, (RR: 0.66 (0.44, 0.99) for any wasting), and RR: 0.45 (0.19, 1.09) for severe wasting. This corresponded to a larger impact on birth weight and a better vaccine match with circulating viruses in cohort 2.
Although maternal immunization reduced low birth weight by 15%, only wasting at 6 months in the 2nd cohort was statistically significantly difference. However, the study was underpowered to detect reductions of public health importance.
Clinicaltrials.gov (NCT01034254).
在南亚的两项随机试验中,母亲接种流感疫苗增加了出生体重,但对婴儿生长的影响尚不清楚。
2011 年 4 月至 2014 年 4 月,在尼泊尔南部平原萨拉里区的两个年度队列中进行了一项全年母亲流感免疫接种的随机安慰剂对照试验。参加试验的妇女所生的婴儿在出生时和 6 个月大时测量体重、身长和头围。该研究有能力进行 3 项主要试验结果,但没有能力进行 6 个月时的发育迟缓或消瘦。
3693 名妇女在 17 至 34 周妊娠期间接受安慰剂或流感疫苗,共分娩 3646 例活产儿。约 72%的存活婴儿在 150 至 210 天龄时进行了体重和身长测量。安慰剂组和疫苗组的发育迟缓发生率(<-2 个 Z 评分身长)分别为 14.8%和 13.6%。< -3 Z 评分的发育迟缓发生率为 3.2%,安慰剂组和疫苗组分别为 2.0%(RR:0.64(95%CI:0.39,1.04))。消瘦(<-2 个 Z 评分体重/身长)发生率安慰剂组为 10.3%,疫苗组为 11.0%。严重消瘦(<-3 个 Z 评分体重/身长)发生率安慰剂组为 3.8%,疫苗组为 2.6%(RR:0.69(95%CI:0.44,1.07))。疫苗对消瘦的影响在第 2 队列中大于第 1 队列(任何消瘦的 RR:0.66(0.44,0.99)),严重消瘦的 RR:0.45(0.19,1.09)。这对应于出生体重的更大影响,以及在第 2 队列中与循环病毒更好的疫苗匹配。
虽然母亲免疫接种使低出生体重减少了 15%,但只有第 2 队列中 6 个月时的消瘦有统计学意义上的差异。然而,该研究的效力不足以检测到具有重要公共卫生意义的减少。
Clinicaltrials.gov(NCT01034254)。